Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to over…
Macro
US · Macroeconomic Factors/Risks · ForecastsLyell Immunopharma, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)
Likelihood Legend A++ is best, F- worst
- A++
- A+
- A
-
Very Unlikely - B+
- B
-
Unlikely
- C+
- C
- D+
- D
- D-
-
Avg.
- E+
- E-
-
Unlikely - F+
- F
- F-
-
Very Unlikely
All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.
All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.